First BEAT-MS Participant has been Enrolled and Randomized

The ITN077AI Clinical Trial Of Autologous Hematopoietic Stem Cell Transplantation Versus Best Available Therapy For Multiple Sclerosis (BEAT-MS) has re-opened for enrollment at Protocol Chair Dr. Jeffrey Cohen’s Cleveland Clinic Foundation site, after a delay related to the COVID-19 pandemic. The BEAT-MS trial will investigate high dose immunosuppression followed by autologous hematopoietic stem cell transplantation compared to the best medical treatment currently available for multiple sclerosis (MS) in participants with relapsing MS.

The first BEAT-MS participant was randomized to the transplant arm of the trial on September 2, 2020. Activation of additional BEAT-MS sites is anticipated in the coming months. You can find more information about BEAT-MS at www.beat-ms.org and ClinicalTrials.gov.